Previous month:
October 2015
Next month:
December 2015

Breezula CB-03-01 Phase 2 Clinical Trial Update for Androgenetic Alopecia #baldness

The benefits of having a topical anti-androgen to treat the progression of Male Pattern Hair Loss or Androgenetic Alopecia is an exciting development to contemplate. It is interesting to see that Cassiopea/Cosmo Pharmaceuticals is undertaking a Phase II proof-of-concept clinical trial in the U.S. using their famed CB-01-03 anti-androgen in a new formulation called Breezula. Here is some information from their website.  --Dr. Bauman

 

BREEZULA™

Breezula™ is the brand name of our anti-androgen-containing composition for the treatment of AGA. Breezula™ is topically delivered to the scalp to reduce the hair miniaturization process that, if not controlled, shrinks the follicle, causing hair thinning and, ultimately, hair loss. Breezula™ is currently undergoing a Phase II proof-of-concept clinical trial in the United States.

PRODUCT DESCRIPTION

Breezula™ is a different formulation of the same API contained in Winlevi™. Breezula™ contains a 5% concentration of this API in a lotion designed to penetrate the scalp.

MECHANISM OF ACTION

Breezula™ acts at cutaneous level on the scalp. It antagonizes the negative effects of dihydrotestosterone, the androgen that is the major contributing factor in AGA, on the dermal papillae, small structure in the skin that nourish the hair follicles. Breezula™ also reduces the skin’s production of prostaglandin D2, a hormone-like compound that, in elevated levels, can inhibit hair growth. Finally, Breezula™ helps to control sebum secretion, ultimately reducing hair miniaturization and dermal inflammation.

Breezula™ does not interfere with the hormonal and, in particular, androgenic profile of patients; libido and sexual behavior are unaffected in clinical trials to date.

 

For information on the latest available treatments for hair loss in men and women, visit http://www.baumanmedical.com and schedule a consultation.